Coronavirus (Covid -19) and Type 2 Diabetes

New safety guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) suggests SGLT2 inhibitor treatment which includes Invokana, should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses and ketone levels measured, preferably in blood rather than urine. Treatment may be restarted when the ketone values are normal and the patient’s condition has stabilised.

It is important that people with diabetes follow the sick day rules should they become ill from any illness.

Prescribing information can be found at the bottom of the page

The Renal Reason to Intensify

Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise.

Both improvement in glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of T2DM.

Request more information

Improvements in renal outcomes with Invokana are additional benefits only and not licensed indications.

Invokana (canagliflozin) Logo - Renal Reason to Intensify
A recommended EASD consensus report 2019 SGLT2i logo

The Renal Reason to Intensify

Invokana is indicated for the treatment of adults with
insufficiently controlled type 2 diabetes mellitus (T2DM)
as an adjunct to diet and exercise.

Both improvement in glycaemic control and reduction of
cardiovascular morbidity and mortality are an integral
part of the treatment of T2DM.

Request more information

Improvements in renal outcomes with Invokana
are additional benefits only and not licensed indications.

Invokana (canagliflozin) Logo - Renal Reason to Intensify

Date of preparation: May 2020 | Job code: UK/INV-18087(2)a